TY - JOUR
T1 - Controlled release of naringenin from soft hydrogel contact lens
T2 - An investigation into lens critical properties and in vitro release
AU - (Chau Thuy) Nguyen, Dan
AU - Dowling, Joseph
AU - Ryan, Richie
AU - McLoughlin, Peter
AU - Fitzhenry, Laurence
N1 - Funding Information:
The authors would like to thank Sean Roche at the Pharmaceutical & Molecular Biotechnology Research Centre, South East Technological Univeristy, for his help in carrying out the XRD analysis of naringenin. We would also like to thank Adrián Martín Prado (3D-NEONET, project's grant number: 734907) for his contribution in examining the robustness of the lens characterization techniques including equilibrium water content and refractive index. We want to extend our acknowledgement to Professor Ana Paula Serro's lab (Instituto Superior Técnico, Lisbon, Portugal) for their training on the lens characterization techniques including wettability and tensile strength. This work was supported by the Irish Research Council-Enterprise Partnership Scheme [grant number: EPSPG/2017/236, 2017].
Funding Information:
This work was supported by the Irish Research Council-Enterprise Partnership Scheme [grant number: EPSPG/2017/236, 2017].
Publisher Copyright:
© 2022 The Authors
PY - 2022/6/1
Y1 - 2022/6/1
N2 - The naringenin (NAR)-impregnated hydrogel lenses (nesofilcon A material) were manufactured in this study with the feasibility to achieve controlled daily drug release. The lenses were fabricated using a comparable commercial-standard process, utilizing injection molding and thermal curing approaches. NAR-loaded lenses were prepared by both direct entrapment and ‘soak and release’ methods. Their critical properties were tested to ISO standards and comparable to the commercial lenses. NAR was fully characterized by studying its physical and chemical stability throughout the manufacturing processes using thermal analysis, high performance liquid chromatography and X-ray diffraction analysis. The NAR-loaded lenses showed > 97% light transmission, >75% water content, 0.50–0.53 ± 0.06 MPa tensile strength, with a lens diameter of 14.1 ± 0.1 mm. Lens polymerization kinetics were studied using differential scanning calorimetry. NAR released from the lens, prepared by a direct entrapment approach, followed a diffusion-controlled mechanism, and provided a controlled drug release of 72–82% for 24 h. A faster release rate was observed for NAR-loaded lenses prepared by a soak and release method, with over 90% of NAR was released in the first five hours.
AB - The naringenin (NAR)-impregnated hydrogel lenses (nesofilcon A material) were manufactured in this study with the feasibility to achieve controlled daily drug release. The lenses were fabricated using a comparable commercial-standard process, utilizing injection molding and thermal curing approaches. NAR-loaded lenses were prepared by both direct entrapment and ‘soak and release’ methods. Their critical properties were tested to ISO standards and comparable to the commercial lenses. NAR was fully characterized by studying its physical and chemical stability throughout the manufacturing processes using thermal analysis, high performance liquid chromatography and X-ray diffraction analysis. The NAR-loaded lenses showed > 97% light transmission, >75% water content, 0.50–0.53 ± 0.06 MPa tensile strength, with a lens diameter of 14.1 ± 0.1 mm. Lens polymerization kinetics were studied using differential scanning calorimetry. NAR released from the lens, prepared by a direct entrapment approach, followed a diffusion-controlled mechanism, and provided a controlled drug release of 72–82% for 24 h. A faster release rate was observed for NAR-loaded lenses prepared by a soak and release method, with over 90% of NAR was released in the first five hours.
KW - Chemical properties
KW - Hydrogel contact lens
KW - In vitro release
KW - Ocular drug delivery
KW - Physical properties
KW - Therapeutic lens
UR - http://www.scopus.com/inward/record.url?scp=85130925235&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2022.121793
DO - 10.1016/j.ijpharm.2022.121793
M3 - Article
C2 - 35526700
AN - SCOPUS:85130925235
SN - 0378-5173
VL - 621
SP - 121793
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 121793
ER -